Australia's most trusted
source of pharma news
Saturday, 14 December 2024
Posted 8 July 2024 AM
After "careful consideration and a thorough review" Mundipharma has decided to reinstate its oral opioid OxyNorm in the Australian market.
It marks roughly six months since the TGA advised that the company was discontinuing supply of the drug, which added to the angst amongst key health bodies about the dwindling availability of critical pain relief medicines in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.